Get in touch →

6 Medical Bracelets that are changing lives in 2026

by | Feb 19, 2026 | Blog, News

The Health & Wellness IoT sector is at a turning point. We’re moving past the era of “gadgets for the sake of gadgets” and into a space where hardware solves genuine, often silent, human struggles. The companies winning right now aren’t just selling sensors: they are scaling clinical outcomes and navigating the complex bridge between consumer tech and medical-grade reliability.

 

Our perspective is based on this reality. Having developed the software layer for Embr Labs’ flagship product, the Embr Wave, we lived the challenge of turning sensor data into a reliable thermal “companion”. Building this product taught us that the real value of IoT isn’t just in the data collected, but in the relief it provides.

 

This report analyses Embr Labs and five other companies redefining personal health technology. We will explore their latest strategic shifts, financial milestones, and the real-world impact they are having as of early 2026.

Since we built the core software for Embr Wave, we’ve seen Embr Labs’ journey up close. Based in Boston, they’re leading the way in thermal wellness with a wearable that gives real, on-demand temperature relief and helps people feel better every day. 

 

The Product: The Embr Wave is a smart wristband that uses patented technology to deliver cooling or warming sensations and help the user find relief and have more control over symptoms like hot flashes, stress, night sweats, chills, and disrupted sleep. As the architects of the software that translates user intent and sensor data into thermal commands, we implemented the AI feature that allows the device to anticipate a hot flash and activate cooling early, a significant leap from a reactive to a proactive health tool.

 

Impact: With a verified user base of over 200,000 customers, Embr Labs has demonstrated significant real-world impact through extensive clinical validation. Their research, conducted in partnership with premier institutions like Johnson & Johnson, Dana-Farber Cancer Institute, and the University of Massachusetts, highlights broad quality of life improvements. Key findings from their studies show that the Embr Wave provides a 28% reduction in the time it takes to fall asleep, a 168% improvement in hot flash control, and a 26% reduction in daytime fatigue. By providing non-pharmacological relief for menopause and general stress symptoms, Embr Labs is demonstrating the power of temperature as a therapeutic tool.

 

WHOOP has established itself as a leader in the performance and recovery space, offering a sophisticated wearable technology platform designed for elite athletes and health-conscious individuals. The company has pioneered a subscription-based model that focuses on continuous monitoring and deep physiological insights. 

 

The Product: WHOOP provides a screenless wrist-worn wearable that continuously monitors key physiological metrics, including heart rate variability (HRV), resting heart rate, respiratory rate, and sleep. The platform translates this data into daily scores for Strain, Recovery, and Sleep, offering personalised coaching through its mobile app. Recent innovations include an AI-powered WHOOP Coach (using OpenAI) and a medical-grade tier (WHOOP MG) with ECG and blood pressure insights. 

 

Impact: With a valuation of $3.6 billion (as of 2021) and over $400 million in funding, WHOOP has significant market traction. Its impact lies in optimising human performance and healthspan, with a strong user base among professional athletes and teams (e.g., Cristiano Ronaldo, LeBron James, Ferrari F1). The platform has also demonstrated clinical utility, particularly in early COVID-19 detection through respiratory rate monitoring. 

Hilo, formerly known as Aktiia, is a Swiss-based health technology company that has developed a revolutionary cuffless blood pressure monitoring system. The company is on a mission to make blood pressure monitoring easy, continuous, and actionable, thereby helping to prevent heart attacks and strokes.

 

The Product: Hilo offers a continuous, cuffless blood pressure monitoring system. The device, worn on the wrist, provides 24/7 blood pressure data without the need for traditional, inflatable cuffs. 

 

Impact: With over 130,000 users globally and a 76% revenue growth in 2025, Hilo is making significant strides in preventative cardiovascular care. A 2025 company report found that users who monitor continuously are four times more likely to achieve their target blood pressure within six months than with traditional methods.

Apollo Neuro is a US company with a wearable that helps your body handle stress better. It uses gentle vibrations to help you feel calm and in control, boosting heart rate variability and reducing stress and anxiety.

 

The Product: The Apollo wearable is a device worn on the wrist or ankle that delivers non-invasive, vibroacoustic stimulation. The bracelet prevents unwanted wake-ups before they happen, make the user sleep longer with 60 minutes more sleep a night, sleep deeper with improved deep and REM sleep.

 

Impact: With over 100,000 users, Apollo Neuro has a significant user base. In 2025, users collectively gained 143.8 million minutes of additional sleep. A clinical trial at Washington State University also showed a significant reduction in burnout among medical students using the device.

Cala Health is changing how we treat chronic diseases with wearable therapies. They focus on helping people with neurological disorders, especially those with essential tremor.

 

The Product: The Cala kIQ system is a prescription-only, wrist-worn device that delivers on-demand electrical stimulation to the wrist’s nerves. This therapy is calibrated to the patient’s tremor frequency to provide effective, temporary relief from hand tremors. 

 

Impact: Cala Health’s therapy is the only on-demand treatment for essential tremor, with clinical data showing that 93% of patients experience therapeutic benefit, and most achieve tremor reduction of over 50% during sessions. The recent positive Medicare Coverage Determination has significantly increased access for seniors, a key demographic for this condition. Cala Health has raised over $250 million in total funding, including a $50 million Series D round in late 2024. This substantial financial backing supports the company’s mission to bring its innovative therapies to a broader audience. 

 

NightWatch is a proven device that alerts caregivers to severe nighttime epileptic seizures. Built in the Netherlands, it gives families and caregivers real peace of mind.

 

The Product: NightWatch is a comfortable armband worn during sleep that continuously monitors heart rate and motion. When it detects a potentially severe seizure, it sends a wireless alert to a caregiver’s base station. 

 

Impact Clinical studies at UMC Utrecht have shown that NightWatch detects 96% of severe nocturnal seizures, providing near-perfect reliability and reducing the risk of SUDEP (Sudden Unexpected Death in Epilepsy). The device is a life-saving tool for individuals with epilepsy.

Vertical Insights: 2026 Market Trends

 

1. The Move Toward Predictive Intervention

The industry has matured from “track and notify” to “predict and prevent.”

  • Embr Labs uses AI to anticipate hot flashes and trigger preemptive cooling.
  • Whoop has integrated “Advanced Labs,” connecting 24/7 wearable data with blood biomarkers to highlight potential risks before they escalate into medical issues.

 

2. Specialised “Micro-Niche” Therapeutics

Generic fitness tracking is being replaced by deep clinical specialisation..

  • Cala Health and NightWatch prove that focusing on a single, high-stakes condition like tremors or nocturnal epilepsy creates a defensible market position through specialist physician relationships and 96% clinical reliability.
  • Apollo Neuro and Embr Labs have pioneered “digital drugs” using haptic and thermal stimulation as non-pharmaceutical treatments for stress and menopause.

 

3. The “Medical-Wellness” Hybrid Business Model

As regulatory pathways become clearer, companies are using tiered access to scale.

  • Apollo Neuro’s freemium software strategy (delivering therapy via smartphone haptics) lowers the barrier to entry for their premium $349 hardware.
  • Whoop has shifted to a multi-tiered membership model, offering specialised “Peak” and “Life” tiers that include medical-grade longevity insights and clinical-grade blood testing.

 

4. Regulatory Navigation: The 2026 Standard

Navigating the FDA is now a standard part of the business roadmap rather than an obstacle.

  • Hilo secured landmark FDA clearance for over-the-counter cuffless blood pressure monitoring, unlocking massive retail potential for 2026.
  • Whoop’s 2025 challenges with “Blood Pressure Insights” culminated in new 2026 FDA guidance that allows optical BP measurements to remain in the wellness category, provided they are marketed as “relative changes” rather than diagnostic “medical-grade” data.

Conclusion: The Wrist as a Therapeutic Interface

As developers who have worked inside this ecosystem, specifically building the software layer for Embr Labs, we believe the sector is just beginning its second act. The “bracelet” is no longer just a convenient location for a sensor; it is a therapeutic interface that delivers neuromodulation, bioelectronic medicine, and life-saving alerts.

 

The companies that will dominate the 2026-2030 cycle are those that balance this clinical rigour with a seamless user experience, turning raw biometric data into active health outcomes.

 

How are you planning to move your device from “activity tracking” to “clinical necessity” in 2026?

 

 

Building the next generation of predictive health tech?

 

Let’s talk about the software that will drive it!

Let's talk!